InsuLine reports positive results for insulin patch

The InsuPatch met its primary endpoint for obtaining FDA approval of the product.

InsuLine Medical Ltd. (TASE: INSL) today announced positive results in the efficacy and safety clinical trial of its insulin patch, InsuPatch for the treatment of Type 1 (juvenile) diabetes. The InsuPatch met its primary endpoint for obtaining US Food and Drug Administration (FDA) approval of the product.

The InsuPatch achieved a relative median increase of 29.7% in insulin levels in the blood within an hour compared with an insulin injection without the product. The FDA requirement was a median increase of at least 10%.

55 patients participated in the clinical trial, and the analysis was conduction on the 51 patients who met the FDA protocols for the trial.

100 patients are participating in the second part of the trial to test InsuPatch's safety. The trial, which began early in 2011, is due to be completed in April 2012. Following the completion of the trial and analysis of the results, InsuLine will submit a certification application for the product with the FDA.

InsuLine's share price rose 14.9% by early afternoon to NIS 0.88, giving a market cap of NIS 48 million.

Published by Globes [online], Israel business news - www.globes-online.com - on December 21, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס